JD, Eli Lilly, Cameco, Coinbase, and Strategy: Trending by Analysts

Analysts are intrested in these 5 stocks: ( (JD) ), ( (LLY) ), ( (CCJ) ), ( (COIN) ) and ( (MSTR) ). Here is a breakdown of their recent ratings and the rationale behind them.

JD.com, a major player in the Chinese e-commerce sector, is currently facing a challenging outlook according to analyst Eddy Wang. The company has been downgraded to a ‘Sell’ rating with a price target of $28. The report highlights JD’s previous gains from trade-in policies, which are now tapering off, leading to a slowdown in revenue growth. Additionally, JD’s continuous investments in new ventures are expected to erode long-term margins and return on equity (ROE). The analyst also notes that JD’s focus on AI is unlikely to provide a significant competitive edge in the near term, further impacting its valuation.

Eli Lilly & Co has received a positive upgrade to ‘Buy’ from analyst David Risinger, driven by the promising prospects of its obesity treatment portfolio. The company is expected to benefit from expanded Medicare and Medicaid access, alongside the launch of new drugs like orforglipron and eloralintide. The analyst anticipates a significant increase in revenue and earnings per share (EPS) over the next few years, bolstered by a strategic deal with the US government. This agreement is projected to expand the potential market for obesity treatments, positioning Eli Lilly as a leader in this growing sector.

Cameco, a key player in the uranium market, has been initiated with a ‘Hold’ rating by analyst George Eadie. The company offers high-quality exposure to the uranium sector, which is expected to see strong demand growth. Cameco’s earnings are projected to rise as it re-contracts sales at higher spot prices, and its partnership with Westinghouse is seen as a positive catalyst. However, the stock is currently trading at a premium, and the analyst remains cautious due to recent price momentum and valuation metrics.

Coinbase Global has been upgraded to ‘Buy’ by analyst Gustavo Gala, with a new price target of $375. The report highlights positive developments in stablecoin utility and potential regulatory changes regarding tokenization of equities. Coinbase’s recent volume trends suggest a return to market share expansion, and upcoming product announcements are expected to further enhance its position. While the company still faces cyclicality, its efforts to diversify revenue streams and improve return on invested capital (ROIC) are seen as promising for future growth.

Strategy, formerly rated as ‘Sell’, has been upgraded to ‘Hold’ by analyst Gustavo Gala. The report acknowledges that key catalysts for the previous bearish thesis have played out, reducing downside pressure. However, the analyst remains cautious about the company’s reliance on Bitcoin holdings and questions the sustainability of its valuation premium. Despite these concerns, the report suggests that holding the stock could be justified for investors with a strong conviction in Bitcoin’s long-term price trajectory.